(Incorporated in Delaware)

We are a Phase 1 clinical biotech that uses our AI platform to design small molecule cancer drugs. We are evaluating our leading drug candidate, IAM 1363, in a Phase 1/1B trial as a therapy for patients with HER2-altered solid tumors. A registrational trial may begin as soon as 2027. 

From the prospectus:

We are a technology and clinical-stage life sciences company pursuing a fundamental shift in the biopharmaceutical industry. Our mission is to make better technology for better medicines. We do this by integrating leading proprietary, large-scale artificial intelligence (AI) with automated, scalable chemistry and biology experimentation. We call this approach molecular superintelligence.

The Iambic molecular superintelligence platform is designed to disrupt legacy drug discovery paradigms. Instead of treating each stage of drug discovery as a distinct technological challenge, we have developed a unified, intelligent platform designed to address the full journey of drug discovery and development—from hit identification to multiparameter lead optimization to clinical developability. Our proprietary technologies include Enchant, a multimodal AI model for predicting preclinical and clinical properties, NeuralPLexer, a flow-matching generative AI for biomolecular structure prediction, and automated plate-based chemistry and biology workflows that allow synthesis and testing of hundreds of compounds per program on a weekly cadence.

Our most advanced program, IAM1363, is an oral, highly selective, pan-mutant, and brain-penetrant small molecule inhibitor of human epidermal growth factor receptor 2 (HER2). As of September 2026, it is in an ongoing, open-label, multi-center Phase 1/1b basket clinical trial in patients with advanced HER2-altered solid tumors, and we anticipate initiating a registrational trial as early as 2027, subject to regulatory feedback. We believe IAM1363 is the only known HER2 tyrosine kinase inhibitor (TKI) that binds to the inactive (DFG-out) conformation of the HER2 kinase domain. We believe this distinct Type II binding mode may contribute to the molecule’s combination of selectivity for HER2 vs wild-type epidermal growth factor receptor (EGFR), and broad coverage against HER2 variants with activating mutations. We believe IAM1363 has the potential to be developed across multiple HER2-driven solid tumor indications, including HER2-positive breast cancer, HER2-positive gastroesophageal adenocarcinoma (GEA), HER2-amplified non-small cell lung cancer (NSCLC), and HER2-mutant NSCLC.

Our internal pipeline includes IAM217, a brain-penetrant allosteric inhibitor for KIF18A, a mitotic kinesin with potential therapeutic relevance for ovarian cancer, triple-negative breast cancer, and other solid-tumor cancers. IAM-C1 is our selective dual inhibitor of cyclin-dependent kinases 2 and 4 (CDK2 and CDK4). We anticipate submitting Investigational New Drug (IND) applications for IAM217 and IAM-C1 in the fourth quarter of 2026, followed in each case by initiation of a Phase 1/2 clinical trial, subject to regulatory clearance.

Note: Net loss and collaboration revenue are for the 12 months that ended on June 30, 2026. 

(Note: Iambic Therapeutics filed its S-1 on Sept. 21, 2026, for its IPO, without disclosing the terms. Estimated proceeds are $100 million, a placeholder figure.)